Form 4: Verastem COO Matthew Ros Acquires 50,000 Shares of Common Stock

Verastem's Chief Operating Officer, Matthew Ros, acquired 50,000 shares of common stock on April 1, 2025, through a grant of restricted stock units.

Summary

• Matthew Ros, the Chief Operating Officer of Verastem, Inc., acquired 50,000 shares of common stock on April 1, 2025.
• The acquisition was in the form of restricted stock units (RSUs) granted under the Issuer's inducement award program.
• Each RSU represents the contingent right to receive one share of Common Stock.
• The RSUs vest as to 25% of the shares on the first anniversary of the grant date, and then 6.25% every three months thereafter until the fourth anniversary, provided Mr. Ros remains an employee.
• Following the transaction, Mr. Ros beneficially owns 50,000 shares of Verastem common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs to the COO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's long-term success.

Risks

• The value of the RSUs is dependent on the future performance of Verastem's stock.
• If Mr. Ros leaves the company before the RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements, but the RSU grant suggests an expectation of continued service from the COO.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the biotechnology industry, used to attract and retain key personnel and align their interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include a mix of salary, bonus, and equity-based awards like RSUs.
• The vesting schedule of these RSUs is fairly standard, with vesting occurring over a period of several years to incentivize long-term commitment.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity compensation strategies for their executives.

Stakeholder Impact

• Shareholders: The RSU grant aligns the COO's interests with those of shareholders, potentially leading to increased value.
• Employees: The grant may have a positive impact on employee morale, as it demonstrates the company's investment in its leadership.

Key Dates

Keywords

Verastem, VSTM, Matthew Ros, Chief Operating Officer, RSU, Restricted Stock Units, Beneficial Ownership, Form 4, Inducement Award Program, Stock Grant, Equity Compensation